小儿非酒精性脂肪肝概述:全科医生指南》。

Asiya K Shakir, Upma Suneja, Kevin R Short, Sirish Palle
{"title":"小儿非酒精性脂肪肝概述:全科医生指南》。","authors":"Asiya K Shakir, Upma Suneja, Kevin R Short, Sirish Palle","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Nonalcoholic fatty liver disease (NAFLD) is rapidly evolving into one of the most common pediatric liver diseases and currently is the most common cause for liver transplantation in young adults. Therefore, early recognition of risk factors, disease prevention, and diagnosis during childhood is paramount for effective management.</p><p><strong>Objective: </strong>The primary objective of this review is to discuss updated recommendations for screening, diagnosis and management of NAFLD. The secondary objective is to review the extent and impact of pediatric NAFLD in Oklahoma through our center's participation in a multi-center prospective study.</p><p><strong>Evidence review: </strong>We reviewed updated guidelines from the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the approach used in our clinic and data from a multi-center collaboration on NAFLD, known as TARGET-NASH.</p><p><strong>Findings: </strong>Our review highlights that obese and Hispanic children are at greatest risk for developing NAFLD. Screening with ALT should be considered between ages 9-11 years for children with BMI more than the 95<sup>th</sup> percentile. Liver biopsy is the gold standard for diagnosis of NAFLD and currently lifestyle modification is the only effective therapy for management of NAFLD.</p><p><strong>Conclusion and relevance: </strong>All obese children, especially those who are Hispanics or have a family history of NAFLD should be considered for screening with serum ALT between the ages of 9 and 11 years. Children with ALT values that are elevated more than twice the upper limit of normal for more than 3 months must be referred to pediatric hepatology for timely evaluation.</p>","PeriodicalId":75127,"journal":{"name":"The Journal of the Oklahoma State Medical Association","volume":"111 8","pages":"806-811"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625810/pdf/nihms-1038256.pdf","citationCount":"0","resultStr":"{\"title\":\"Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners.\",\"authors\":\"Asiya K Shakir, Upma Suneja, Kevin R Short, Sirish Palle\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>Nonalcoholic fatty liver disease (NAFLD) is rapidly evolving into one of the most common pediatric liver diseases and currently is the most common cause for liver transplantation in young adults. Therefore, early recognition of risk factors, disease prevention, and diagnosis during childhood is paramount for effective management.</p><p><strong>Objective: </strong>The primary objective of this review is to discuss updated recommendations for screening, diagnosis and management of NAFLD. The secondary objective is to review the extent and impact of pediatric NAFLD in Oklahoma through our center's participation in a multi-center prospective study.</p><p><strong>Evidence review: </strong>We reviewed updated guidelines from the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the approach used in our clinic and data from a multi-center collaboration on NAFLD, known as TARGET-NASH.</p><p><strong>Findings: </strong>Our review highlights that obese and Hispanic children are at greatest risk for developing NAFLD. Screening with ALT should be considered between ages 9-11 years for children with BMI more than the 95<sup>th</sup> percentile. Liver biopsy is the gold standard for diagnosis of NAFLD and currently lifestyle modification is the only effective therapy for management of NAFLD.</p><p><strong>Conclusion and relevance: </strong>All obese children, especially those who are Hispanics or have a family history of NAFLD should be considered for screening with serum ALT between the ages of 9 and 11 years. Children with ALT values that are elevated more than twice the upper limit of normal for more than 3 months must be referred to pediatric hepatology for timely evaluation.</p>\",\"PeriodicalId\":75127,\"journal\":{\"name\":\"The Journal of the Oklahoma State Medical Association\",\"volume\":\"111 8\",\"pages\":\"806-811\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625810/pdf/nihms-1038256.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of the Oklahoma State Medical Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Oklahoma State Medical Association","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

重要性:非酒精性脂肪肝(NAFLD)正迅速发展成为最常见的儿科肝病之一,目前也是青壮年肝移植的最常见原因。因此,在儿童时期及早识别风险因素、预防疾病和进行诊断对于有效治疗至关重要:本综述的主要目的是讨论非酒精性脂肪肝的筛查、诊断和管理的最新建议。次要目的是通过我们中心参与的一项多中心前瞻性研究,回顾俄克拉荷马州小儿非酒精性脂肪肝的程度和影响:我们回顾了北美儿科胃肠病学、肝病学和营养学学会(NASPGHAN)的最新指南、我们诊所采用的方法以及一项名为 TARGET-NASH 的非酒精性脂肪肝多中心合作研究的数据:我们的研究结果表明,肥胖儿童和西班牙裔儿童患非酒精性脂肪肝的风险最大。对于体重指数(BMI)超过第95百分位数的儿童,应考虑在9-11岁期间进行谷丙转氨酶(ALT)筛查。肝脏活检是诊断非酒精性脂肪肝的金标准,目前,改变生活方式是治疗非酒精性脂肪肝的唯一有效疗法:所有肥胖儿童,尤其是西班牙裔儿童或有非酒精性脂肪肝家族史的儿童,都应考虑在 9 至 11 岁期间接受血清 ALT 筛查。ALT 值升高超过正常值上限两倍且持续时间超过 3 个月的儿童必须及时转诊至儿科肝病科进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners.

Importance: Nonalcoholic fatty liver disease (NAFLD) is rapidly evolving into one of the most common pediatric liver diseases and currently is the most common cause for liver transplantation in young adults. Therefore, early recognition of risk factors, disease prevention, and diagnosis during childhood is paramount for effective management.

Objective: The primary objective of this review is to discuss updated recommendations for screening, diagnosis and management of NAFLD. The secondary objective is to review the extent and impact of pediatric NAFLD in Oklahoma through our center's participation in a multi-center prospective study.

Evidence review: We reviewed updated guidelines from the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the approach used in our clinic and data from a multi-center collaboration on NAFLD, known as TARGET-NASH.

Findings: Our review highlights that obese and Hispanic children are at greatest risk for developing NAFLD. Screening with ALT should be considered between ages 9-11 years for children with BMI more than the 95th percentile. Liver biopsy is the gold standard for diagnosis of NAFLD and currently lifestyle modification is the only effective therapy for management of NAFLD.

Conclusion and relevance: All obese children, especially those who are Hispanics or have a family history of NAFLD should be considered for screening with serum ALT between the ages of 9 and 11 years. Children with ALT values that are elevated more than twice the upper limit of normal for more than 3 months must be referred to pediatric hepatology for timely evaluation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical question: Can virtual reality be an effective adjunctive to conventional treatment in patients with chronic lower back pain? Hospital Admission Rates and Mortality Among Emergency Department Patients with COVID-19 Discharged with Remote Patient Monitoring with or without HO2ME - A Value-Based Approach. Investigation of Geographical Disparities: The Use of An Interpolation Method For Cancer Registry Data. In patients with osteoarthritis, is curcumin, compared to placebo, effective in reducing pain? A Snapshot of Oklahoma's CHR/CHW Workforce: Results from the Region 6 Training Needs Assessment Survey, 2019.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1